HUE063586T2 - Piridazinon-vegyületek és alkalmazásaik - Google Patents
Piridazinon-vegyületek és alkalmazásaikInfo
- Publication number
- HUE063586T2 HUE063586T2 HUE19835997A HUE19835997A HUE063586T2 HU E063586 T2 HUE063586 T2 HU E063586T2 HU E19835997 A HUE19835997 A HU E19835997A HU E19835997 A HUE19835997 A HU E19835997A HU E063586 T2 HUE063586 T2 HU E063586T2
- Authority
- HU
- Hungary
- Prior art keywords
- pyridazinone compounds
- pyridazinone
- compounds
- Prior art date
Links
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862756553P | 2018-11-06 | 2018-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE063586T2 true HUE063586T2 (hu) | 2024-01-28 |
Family
ID=69160036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE19835997A HUE063586T2 (hu) | 2018-11-06 | 2019-11-06 | Piridazinon-vegyületek és alkalmazásaik |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11091464B2 (hu) |
| EP (2) | EP3877376B1 (hu) |
| JP (2) | JP7162132B2 (hu) |
| KR (1) | KR20210100094A (hu) |
| CN (1) | CN113272291A (hu) |
| AU (1) | AU2019376065A1 (hu) |
| BR (1) | BR112021008905A2 (hu) |
| CA (1) | CA3118934A1 (hu) |
| DK (1) | DK3877376T3 (hu) |
| EA (1) | EA202191084A1 (hu) |
| ES (1) | ES2958954T3 (hu) |
| FI (1) | FI3877376T3 (hu) |
| HR (1) | HRP20231389T1 (hu) |
| HU (1) | HUE063586T2 (hu) |
| IL (1) | IL282998A (hu) |
| LT (1) | LT3877376T (hu) |
| MX (1) | MX2021005350A (hu) |
| PL (1) | PL3877376T3 (hu) |
| PT (1) | PT3877376T (hu) |
| RS (1) | RS64828B1 (hu) |
| SG (1) | SG11202104713RA (hu) |
| SI (1) | SI3877376T1 (hu) |
| WO (1) | WO2020097266A1 (hu) |
| ZA (1) | ZA202103260B (hu) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU231285B1 (hu) | 2018-04-18 | 2022-08-28 | Printnet Kereskedelmi És Szolgáltató Kft. | A miozin-2-izoformákat szelektíven gátló, gyógyászatilag hatásos vegyületek |
| EP3877367B1 (en) | 2018-11-06 | 2024-05-22 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| WO2020097265A1 (en) | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| CA3118934A1 (en) | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| EP4149467A1 (en) * | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| EP4149465A1 (en) * | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| EP4149620A1 (en) * | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Pyridazinone compounds for the treatment of neuromuscular diseases |
| WO2021231630A1 (en) * | 2020-05-13 | 2021-11-18 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| JP2023526247A (ja) * | 2020-05-13 | 2023-06-21 | エッジワイズ セラピューティクス， インコーポレイテッド | 神経筋疾患の処置のためのピリダジノン化合物 |
| WO2023091606A1 (en) * | 2021-11-17 | 2023-05-25 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| WO2023220180A1 (en) * | 2022-05-11 | 2023-11-16 | Edgewise Therapeutics, Inc. | Methods of manufacturing pyridazinone compounds |
| WO2024055007A1 (en) | 2022-09-09 | 2024-03-14 | Edgewise Therapeutics, Inc. | Pyridazinone compositions for the treatment of neuromuscular conditions |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6140270A (ja) | 1984-08-01 | 1986-02-26 | Morishita Seiyaku Kk | ピリダジノン誘導体 |
| DD286354A5 (de) | 1989-08-08 | 1991-01-24 | Karl-Marx-Universitaet Leipzig,De | Verfahren zur herstellung substituierter 2-carbamoyl-methyl-4-phenyl-1,2,5,6-tetrahydro- und 1,2-dihydro-1-oxo-pyridazine |
| EP0478195B1 (en) | 1990-09-21 | 1999-05-26 | Rohm And Haas Company | Dihydropyridazinones and pyridazinones as fungicides |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| WO1995026325A2 (en) | 1994-03-25 | 1995-10-05 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
| IL118631A (en) | 1995-06-27 | 2002-05-23 | Tanabe Seiyaku Co | History of pyridazinone and processes for their preparation |
| DE19629817A1 (de) | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
| SK17052002A3 (sk) | 2000-06-05 | 2003-12-02 | Altana Pharma Ag | Pyridazinónové zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie |
| MXPA05009500A (es) | 2003-03-07 | 2005-10-18 | Kowa Co | Derivado de benzofurano. |
| JP4890439B2 (ja) | 2005-03-07 | 2012-03-07 | 杏林製薬株式会社 | ピラゾロピリジン−４−イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤 |
| WO2007044796A2 (en) | 2005-10-11 | 2007-04-19 | Nps Pharmaceuticals, Inc. | Pyridazinone compounds as calcilytics |
| DE102005057924A1 (de) | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| PL2069312T3 (pl) | 2006-07-25 | 2013-03-29 | Cephalon Inc | Pochodne pirydazynonu |
| MX2009008531A (es) | 2007-02-16 | 2009-08-26 | Amgen Inc | Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met. |
| DE102007025717A1 (de) | 2007-06-01 | 2008-12-11 | Merck Patent Gmbh | Arylether-pyridazinonderivate |
| DE102007025718A1 (de) | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102007038957A1 (de) | 2007-08-17 | 2009-02-19 | Merck Patent Gmbh | 6-Thioxo-pyridazinderivate |
| DE102008019907A1 (de) | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | Pyridazinonderivate |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| AR081626A1 (es) * | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| WO2012021707A2 (en) | 2010-08-11 | 2012-02-16 | The Regents Of The University Of California | Premature-termination-codons readthrough compounds |
| CA2809662C (en) | 2010-09-01 | 2019-04-16 | Gilead Connecticut, Inc. | Pyridazinones, method of making, and method of use thereof |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| WO2013057101A1 (de) | 2011-10-17 | 2013-04-25 | Bayer Intellectual Property Gmbh | Substituierte oxadiazolylpyridinone und - pyridazinone als hif - hemmer |
| CN103570730A (zh) | 2012-08-01 | 2014-02-12 | 中国科学院上海药物研究所 | 具有桥环结构的稠环哒嗪酮类化合物及其制备方法和用途 |
| WO2014031928A2 (en) | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
| US9566310B2 (en) * | 2012-09-10 | 2017-02-14 | Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno | Methods of treating muscular dystrophy |
| WO2014055644A2 (en) | 2012-10-02 | 2014-04-10 | New York University | Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated rna decay |
| AU2013365926B9 (en) | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| HUE032863T2 (hu) * | 2013-02-07 | 2017-11-28 | Merck Patent Gmbh | Piridazinonamid-származékok |
| CA2906008C (en) | 2013-03-13 | 2019-07-09 | Flatley Discovery Lab, Llc | Pyridazinone compounds and methods for the treatment of cystic fibrosis |
| CN106467495A (zh) * | 2015-08-19 | 2017-03-01 | 中国科学院上海药物研究所 | 哒嗪酮类化合物、其制备方法、药物组合物及用途 |
| AU2017348183A1 (en) | 2016-10-26 | 2019-05-16 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating CFTR |
| AU2017348182A1 (en) | 2016-10-26 | 2019-05-16 | Proteostasis Therapeutics, Inc. | N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis |
| AU2017348186A1 (en) * | 2016-10-26 | 2019-05-16 | Proteostasis Therapeutics, Inc | Pyridazine derivatives, compositions and methods for modulating CFTR |
| CN110573161A (zh) | 2017-03-28 | 2019-12-13 | 勃林格殷格翰国际有限公司 | 用于治疗肌营养不良的方法的尼达尼布 |
| TW202334101A (zh) | 2017-04-06 | 2023-09-01 | 美商富曼西公司 | 殺真菌之噁二唑 |
| US20180303821A1 (en) | 2017-04-24 | 2018-10-25 | BraneQuest, Inc. | Membrane active molecules |
| BE1025518B1 (fr) | 2017-08-30 | 2019-04-03 | E2 Drives Sa | Groupe motopropulseur |
| WO2019084499A1 (en) | 2017-10-27 | 2019-05-02 | Genea Biocells USA (Holdings), Inc. | INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION |
| CN118028130A (zh) | 2018-05-17 | 2024-05-14 | 保尔特纺织品公司 | 用于改善重组蛋白分泌的sec经修饰菌株 |
| CN112533601A (zh) | 2018-06-04 | 2021-03-19 | 俄亥俄州创新基金会 | Eaat2活化剂及其使用方法 |
| EP3828174A4 (en) | 2018-07-19 | 2022-08-17 | Sumitomo Pharma Co., Ltd. | PYRIDAZINONE DERIVATIVE |
| CN108947912B (zh) | 2018-07-31 | 2021-10-01 | 中国人民解放军总医院 | 一种靶向Neddylation通路的抗肿瘤化合物 |
| EP3877367B1 (en) | 2018-11-06 | 2024-05-22 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| CA3118934A1 (en) | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| WO2020097265A1 (en) | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| EP4149465A1 (en) | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| EP4149467A1 (en) | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| EP4149620A1 (en) | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Pyridazinone compounds for the treatment of neuromuscular diseases |
| WO2021231630A1 (en) | 2020-05-13 | 2021-11-18 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| JP2023526247A (ja) | 2020-05-13 | 2023-06-21 | エッジワイズ セラピューティクス， インコーポレイテッド | 神経筋疾患の処置のためのピリダジノン化合物 |
| WO2023091606A1 (en) | 2021-11-17 | 2023-05-25 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| WO2024055007A1 (en) | 2022-09-09 | 2024-03-14 | Edgewise Therapeutics, Inc. | Pyridazinone compositions for the treatment of neuromuscular conditions |
-
2019
- 2019-11-06 CA CA3118934A patent/CA3118934A1/en active Pending
- 2019-11-06 PT PT198359978T patent/PT3877376T/pt unknown
- 2019-11-06 FI FIEP19835997.8T patent/FI3877376T3/fi active
- 2019-11-06 DK DK19835997.8T patent/DK3877376T3/da active
- 2019-11-06 HU HUE19835997A patent/HUE063586T2/hu unknown
- 2019-11-06 HR HRP20231389TT patent/HRP20231389T1/hr unknown
- 2019-11-06 MX MX2021005350A patent/MX2021005350A/es unknown
- 2019-11-06 ES ES19835997T patent/ES2958954T3/es active Active
- 2019-11-06 PL PL19835997.8T patent/PL3877376T3/pl unknown
- 2019-11-06 AU AU2019376065A patent/AU2019376065A1/en active Pending
- 2019-11-06 EA EA202191084A patent/EA202191084A1/ru unknown
- 2019-11-06 RS RS20231080A patent/RS64828B1/sr unknown
- 2019-11-06 CN CN201980088114.7A patent/CN113272291A/zh active Pending
- 2019-11-06 BR BR112021008905-5A patent/BR112021008905A2/pt unknown
- 2019-11-06 KR KR1020217016684A patent/KR20210100094A/ko unknown
- 2019-11-06 SI SI201930610T patent/SI3877376T1/sl unknown
- 2019-11-06 EP EP19835997.8A patent/EP3877376B1/en active Active
- 2019-11-06 LT LTEPPCT/US2019/060157T patent/LT3877376T/lt unknown
- 2019-11-06 SG SG11202104713RA patent/SG11202104713RA/en unknown
- 2019-11-06 JP JP2021524227A patent/JP7162132B2/ja active Active
- 2019-11-06 EP EP23189000.5A patent/EP4248973A3/en active Pending
- 2019-11-06 WO PCT/US2019/060157 patent/WO2020097266A1/en active Application Filing
-
2020
- 2020-11-03 US US17/088,469 patent/US11091464B2/en active Active
-
2021
- 2021-05-06 IL IL282998A patent/IL282998A/en unknown
- 2021-05-13 ZA ZA2021/03260A patent/ZA202103260B/en unknown
- 2021-06-11 US US17/345,909 patent/US12012395B2/en active Active
-
2022
- 2022-10-17 JP JP2022166276A patent/JP7429750B2/ja active Active
-
2023
- 2023-09-01 US US18/460,464 patent/US20240025879A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RS64828B1 (sr) | 2023-12-29 |
| JP2022506687A (ja) | 2022-01-17 |
| LT3877376T (lt) | 2023-09-11 |
| ES2958954T3 (es) | 2024-02-16 |
| ZA202103260B (en) | 2023-01-25 |
| SI3877376T1 (sl) | 2023-10-30 |
| EP3877376A1 (en) | 2021-09-15 |
| DK3877376T3 (da) | 2023-10-02 |
| US20240025879A1 (en) | 2024-01-25 |
| SG11202104713RA (en) | 2021-06-29 |
| PT3877376T (pt) | 2023-09-21 |
| US20220106291A1 (en) | 2022-04-07 |
| MX2021005350A (es) | 2021-08-11 |
| WO2020097266A1 (en) | 2020-05-14 |
| US12012395B2 (en) | 2024-06-18 |
| EP3877376B1 (en) | 2023-08-23 |
| IL282998A (en) | 2021-06-30 |
| CA3118934A1 (en) | 2020-05-14 |
| PL3877376T3 (pl) | 2024-02-19 |
| EA202191084A1 (ru) | 2021-10-19 |
| EP4248973A3 (en) | 2023-12-06 |
| JP7162132B2 (ja) | 2022-10-27 |
| KR20210100094A (ko) | 2021-08-13 |
| EP4248973A2 (en) | 2023-09-27 |
| HRP20231389T1 (hr) | 2024-03-01 |
| JP2022179796A (ja) | 2022-12-02 |
| CN113272291A (zh) | 2021-08-17 |
| US20210188814A1 (en) | 2021-06-24 |
| AU2019376065A1 (en) | 2021-05-27 |
| FI3877376T3 (fi) | 2023-09-26 |
| BR112021008905A2 (pt) | 2021-08-10 |
| US11091464B2 (en) | 2021-08-17 |
| JP7429750B2 (ja) | 2024-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202103260B (en) | Pyridazinone compounds and uses thereof | |
| ZA202103231B (en) | Pyridazinone compounds and uses thereof | |
| IL273236A (en) | Pyrazolopyrimidine compounds and their uses | |
| IL285178A (en) | compounds and their use | |
| GB201803568D0 (en) | Novel compounds and uses | |
| IL285177A (en) | compounds and their use | |
| GB201714745D0 (en) | New compounds and uses | |
| GB201714740D0 (en) | New compounds and uses | |
| IL277502A (en) | Compounds and uses for them | |
| GB201714734D0 (en) | New compounds and uses | |
| IL286497A (en) | compounds and their use | |
| IL279483A (en) | Cyanotriazole compounds and their uses | |
| IL291499A (en) | Azaquinoline compounds and their uses | |
| IL284764A (en) | compounds and their uses | |
| IL280644A (en) | Magnesium serine compound and its use | |
| GB201714736D0 (en) | New compounds and uses | |
| IL285118A (en) | compounds and their uses | |
| GB201812078D0 (en) | Novel compounds and their uses | |
| GB201801102D0 (en) | New compounds and uses | |
| GB201712110D0 (en) | New compounds and uses | |
| IL280369A (en) | Myokines and their uses | |
| GB201806349D0 (en) | New compounds and uses | |
| ZA202201239B (en) | Aminothiolester compounds and uses thereof | |
| GB201810667D0 (en) | New compounds and uses | |
| IL283540A (en) | Dock1 inhibitory compound and use thereof |